Stopped: No patient included at target sample sizes
This study is planned to compare the clinical efficacy and safety of aerosolized plus intravenous colistin vs. intravenous colistin as adjunctive therapy for the treatment of ventilator-associated pneumonia (VAP) due to pandrugs-resistant (PDR) Acinetobacter baumannii in the neonates.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Patients With Cure
Timeframe: Through study completion, an average of 2 weeks
Number of Patients With Improved
Timeframe: Through study completion, an average of 2 weeks
Number of Patients With Failure
Timeframe: Through study completion, an average of 2 weeks
Number of Patients With Death
Timeframe: Through study completion, an average of 2 weeks